Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Cancer Health Center

Font Size

Genetic Clues to Cancer Risk From GERD

Researchers Use Genetic Markers to Identify GERD Patients at Risk for Esophageal Cancer

Gene Testing and Colon Cancer Treatment

Obel also announced new ASCO guidelines recommending that people with metastatic colorectal cancer be tested for KRAS gene mutations before undergoing treatment with the targeted drugs Erbitux and Vectibix.

Studies have demonstrated that only patients whose tumors have the normal form of the KRAS gene respond to treatment with the drugs. It is estimated that 40% of colon cancer patients have KRAS gene mutations and will not benefit, Obel says.

Weeding out people who will not benefit from Erbitux and Vectibix will result in significant cost savings to the health care system while sparing patients from side effects of ineffective therapy, Obel tells WebMD.

An economic analysis being presented at the meeting found that routine testing for KRAS gene mutations in patients with metastatic colorectal cancer could save the U.S. health system up to $604 million per year in the cost of Erbitux alone.

Genes Predict Response to Pancreatic Cancer Treatment

In a third study being presented at the symposium, researchers found that certain genetic variations may help predict whether people with pancreatic cancer will respond to treatment.

The researchers examined 15 variants in eight genes involved in repairing DNA damage caused by cancer treatment.

They found that 94% of pancreatic cancer patients with "good" gene variants responded to treatment with radiation and the chemotherapy drug Gemzar, compared with only 73% of people with "bad" gene variants.

People with good gene variants also lived longer. They survived a median of 25.5 months vs. 7.4 months for the "bad" genotype carriers, says Donghui Li, PhD, of the University of Texas M.D. Anderson Cancer Center in Houston.

Taken together, all "the studies bring us closer to the goal of distinguishing those patients most likely to benefit from screening and treatment from those who will not," Obel says.

1 | 2

Today on WebMD

Colorectal cancer cells
New! I AM Not Cancer Facebook Group
Lung cancer xray
See it in pictures, plus read the facts.
sauteed cherry tomatoes
Fight cancer one plate at a time.
Ovarian cancer illustration
Real Cancer Perspectives
Jennifer Goodman Linn self-portrait
what is your cancer risk
colorectal cancer treatment advances
breast cancer overview slideshow
prostate cancer overview
lung cancer overview slideshow
ovarian cancer overview slideshow
Actor Michael Douglas